Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-216P2 SAD Safety and PK Study in Healthy Volunteers
NCT06772870Phase 1Not yet recruiting
- Sponsor
- Design Therapeutics
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Friedreich ataxia (FA) comparing DT-216P2 with Placebo (2 arms). Primary endpoint: Frequency of treatment emergent adverse events at Day 30. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
DT-216
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT06772870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772870.